As a result, we speculate that DJ-1 may be a potential biomarker for evaluating the prognosis of radiotherapy and a synchronous therapeutic target to enhance the efficacy of radiotherapy in ESCC. Here, PARK7 is linked to esophageal squamous cell carcinoma.